Boston Scientific Announces Preliminary Information on U.S. TAXUS Sales for May 1 - 14
(May 18, 2004) -- Boston Scientific Corporation (NYSE: BSX) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for May 1 through May 14.

Preliminary net U.S. sales of TAXUS systems for the period (10 selling days) were approximately $78 million. The Company said it was shipping to approximately 1,200 accounts at the end of the period.

The Company estimates that its share of the U.S. drug-eluting stent market - as of May 14 - continues to be in excess of 70 percent, on a reorder basis.

The Company estimates the adoption rate for drug-eluting stents in the United States - as of May 14 - to be in excess of 75 percent. The adoption rate represents the number of drug-eluting stents placed as a percentage of total stents placed.

The information in this news release is being provided to ensure fair disclosure to all investors in accordance with the Fair Disclosure regulations of the U.S. Securities and Exchange Commission. The Company plans to provide similar information periodically in the coming months.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit:

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, regulatory approvals, competitive offerings, intellectual property, litigation, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.